<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>China</title>
    <description>
      <![CDATA[]]>
    </description>
    <link>https://www.bioworld.com/rss</link>
    <language>en-us</language>
    <item>
      <title>China med-tech raises: Star Sports’ $105M IPO; Cofoe nabs $133M</title>
      <description>
        <![CDATA[Star Sports Medicine Co. Ltd. debuted on the Hong Kong Stock Exchange with an HK$829.55 million (US$105.86 million) IPO May 5, with shares closing about 118% higher on the first day.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730868</guid>
      <pubDate>Wed, 06 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730868-china-med-tech-raises-star-sports-105m-ipo-cofoe-nabs-133m</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2026/HK-Star-Sports-IPO-5-6.webp?t=1778095416" type="image/jpeg" medium="image" fileSize="144071">
        <media:title type="plain">​Star Sports Medicine HKEX IPO ceremony</media:title>
        <media:description type="plain">Star Sports Medicine's IPO ceremony on May 5.
Credit: HKEX; x.com – @HKEXGroup</media:description>
      </media:content>
    </item>
    <item>
      <title>Multiple appearances on Priority Watch List leading to action?</title>
      <description>
        <![CDATA[It’s a sure bet when the U.S. Trade Representative releases its annual Special 301 Report that Chile, China, India, Indonesia, Russia and Venezuela will be on the Priority Watch List. The 2026 report was no exception.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730867</guid>
      <pubDate>Wed, 06 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730867-multiple-appearances-on-priority-watch-list-leading-to-action</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Misc/Magnifying-glass-on-wooden-table.webp?t=1721409551" type="image/jpeg" medium="image" fileSize="152426">
        <media:title type="plain">Magnifying glass on wooden table</media:title>
      </media:content>
    </item>
    <item>
      <title>GSK licenses siRNA asset in $1B deal for Siranbio</title>
      <description>
        <![CDATA[In a deal that could be worth up to $1 billion for Suzhou Siran Biotechnology Co. Ltd. (Siranbio), GSK plc licensed exclusive worldwide rights to the siRNA oligonucleotide SA-030, which has recently entered phase I trials for cardiometabolic disease.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730864</guid>
      <pubDate>Wed, 06 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730864-gsk-licenses-sirna-asset-in-1b-deal-for-siranbio</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/siRNA-structure-model.webp?t=1732119622" type="image/jpeg" medium="image" fileSize="568771">
        <media:title type="plain">Illustration of siRNA structure</media:title>
      </media:content>
    </item>
    <item>
      <title>Simcere Zaiming’s SIM-0613 cleared to enter clinic in China</title>
      <description>
        <![CDATA[Simcere Zaiming Pharmaceutical Co. Ltd.’s SIM-0613 for injection has received clinical trial approval from China’s National Medical Products Administration (NMPA), enabling initiation of a clinical trial for advanced solid tumors.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730909</guid>
      <pubDate>Wed, 06 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730909-simcere-zaimings-sim-0613-cleared-to-enter-clinic-in-china</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/Cancer-cell-antibody-attack.webp?t=1588880107" type="image/png" medium="image" fileSize="559822">
        <media:title type="plain">Antibodies attacking cancer cell </media:title>
      </media:content>
    </item>
    <item>
      <title>Bio Korea 2026: US policy risks shift to execution framework</title>
      <description>
        <![CDATA[Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies can tailor regulatory strategies early, and across the entire development cycle.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730926</guid>
      <pubDate>Tue, 05 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730926-bio-korea-2026-us-policy-risks-shift-to-execution-framework</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Misc/Strategy-compass.webp?t=1777923242" type="image/jpeg" medium="image" fileSize="113016">
        <media:title type="plain">Strategy compass</media:title>
      </media:content>
    </item>
    <item>
      <title>Beone eyes Huahui Health’s trispecific HH-160 with $2B option deal</title>
      <description>
        <![CDATA[Beone Medicines Ltd. gained an exclusive option to develop cancer immunotherapy HH-160 worldwide in a deal potentially worth more than $2 billion for Huahui Health Ltd., the developer of the trispecific antibody.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730925</guid>
      <pubDate>Tue, 05 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730925-beone-eyes-huahui-healths-trispecific-hh-160-with-2b-option-deal</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Drugs/Antibodies.webp?t=1588025814" type="image/png" medium="image" fileSize="452955">
        <media:title type="plain">Antibodies</media:title>
      </media:content>
    </item>
    <item>
      <title>China’s new IIT rules could reshape early stage drug development </title>
      <description>
        <![CDATA[China’s investigator-initiated trial (IIT) system is increasingly being used to generate early human data in cell and gene therapies, and new changes that widen the pathway are expected to drive more multinational companies to conduct IITs in China, panelists said during the Chinabio Partnering Forum in Shanghai April 28-29.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730924</guid>
      <pubDate>Tue, 05 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730924-chinas-new-iit-rules-could-reshape-early-stage-drug-development</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Digital-health-DNA-gene-therapy-research.webp?t=1686951391" type="image/jpeg" medium="image" fileSize="229766">
        <media:title type="plain">Art concept for gene therapy research</media:title>
      </media:content>
    </item>
    <item>
      <title>How to Summit up? Dis-Harmoni on ivonescimab NSCLC phase III</title>
      <description>
        <![CDATA[Wall Street pundits were divided about the likely fate of ivonescimab, Summit Therapeutics Inc.’s bispecific antibody partnered with Akeso Pharmaceuticals Inc., of Hong Kong, and undergoing phase III testing in first-line squamous non-small-cell lung cancer (NSCLC).]]>
      </description>
      <guid>http://www.bioworld.com/articles/730921</guid>
      <pubDate>Tue, 05 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730921-how-to-summit-up-dis-harmoni-on-ivonescimab-nsclc-phase-iii</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/Lung-cancer-xray.webp?t=1663711137" type="image/png" medium="image" fileSize="257656">
        <media:title type="plain">Xray showing lung cancer on tablet</media:title>
      </media:content>
    </item>
    <item>
      <title>Bio Korea 2026: US policy risks shift to execution framework</title>
      <description>
        <![CDATA[Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies can tailor regulatory strategies early, and across the entire development cycle.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730835</guid>
      <pubDate>Mon, 04 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730835-bio-korea-2026-us-policy-risks-shift-to-execution-framework</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Misc/Strategy-compass.webp?t=1777923242" type="image/jpeg" medium="image" fileSize="113016">
        <media:title type="plain">Strategy compass</media:title>
      </media:content>
    </item>
    <item>
      <title>Beone eyes Huahui Health’s trispecific HH-160 with $2B option deal</title>
      <description>
        <![CDATA[Beone Medicines Ltd. gained an exclusive option to develop cancer immunotherapy HH-160 worldwide in a deal potentially worth more than $2 billion for Huahui Health Ltd., the developer of the trispecific antibody.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730878</guid>
      <pubDate>Mon, 04 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730878-beone-eyes-huahui-healths-trispecific-hh-160-with-2b-option-deal</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Drugs/Antibodies.webp?t=1588025814" type="image/png" medium="image" fileSize="452955">
        <media:title type="plain">Antibodies</media:title>
      </media:content>
    </item>
    <item>
      <title>Beone eyes Huahui Health’s trispecific HH-160 with $2B option deal</title>
      <description>
        <![CDATA[Beone Medicines Ltd. gained an exclusive option to develop cancer immunotherapy HH-160 worldwide in a deal potentially worth more than $2 billion for Huahui Health Ltd., the developer of the trispecific antibody.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730749</guid>
      <pubDate>Thu, 30 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730749-beone-eyes-huahui-healths-trispecific-hh-160-with-2b-option-deal</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Drugs/Antibodies.webp?t=1588025814" type="image/png" medium="image" fileSize="452955">
        <media:title type="plain">Antibodies</media:title>
      </media:content>
    </item>
    <item>
      <title>China’s new IIT rules could reshape early stage drug development </title>
      <description>
        <![CDATA[China’s investigator-initiated trial (IIT) system is increasingly being used to generate early human data in cell and gene therapies, and new changes that widen the pathway are expected to drive more multinational companies to conduct IITs in China, panelists said during the Chinabio Partnering Forum in Shanghai April 28-29.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730684</guid>
      <pubDate>Wed, 29 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730684-chinas-new-iit-rules-could-reshape-early-stage-drug-development</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Digital-health-DNA-gene-therapy-research.webp?t=1686951391" type="image/jpeg" medium="image" fileSize="229766">
        <media:title type="plain">Art concept for gene therapy research</media:title>
      </media:content>
    </item>
    <item>
      <title>Akeso sets durability bar as immuno-oncology 2.0 race heats up </title>
      <description>
        <![CDATA[Akeso Pharmaceuticals Inc. has raised the bar for next-generation immuno-oncology, reporting more than 23 months median overall survival in pancreatic cancer with its PD-1/CTLA-4 bispecific antibody cadonilimab, as emerging competitors begin to post earlier signals across solid tumors at the American Association for Cancer Research annual meeting in San Diego April 17 to 22.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730786</guid>
      <pubDate>Tue, 28 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730786-akeso-sets-durability-bar-as-immuno-oncology-20-race-heats-up</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Endocrine-metabolic-pancreas-anatomy-illustration.webp?t=1774020868" type="image/jpeg" medium="image" fileSize="655771">
        <media:title type="plain">Pancreas anatomy illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Ribo, Diagens tally 2 Hong Kong biotech, medtech IPOs in Q1 2026 </title>
      <description>
        <![CDATA[Ribo Life Science Co. Ltd.’s HK$1.8 billion (US$230 million) raise on Jan. 9 was the sole Chinese biotech IPO on the Hong Kong Stock Exchange in the first quarter (Q1) of 2026, despite a growing backlog of more than 70 filings from China life science firms in 2025. Among med-tech companies, Hangzhou Diagens Biotechnology Co. Ltd. debuted with a $101 million Hong Kong IPO March 30, 2026.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730785</guid>
      <pubDate>Tue, 28 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730785-ribo-diagens-tally-2-hong-kong-biotech-medtech-ipos-in-q1-2026</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Hong-Kong-HKEX.webp?t=1588782956" type="image/png" medium="image" fileSize="582891">
        <media:title type="plain">Hong Kong stock market illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Chinese biotechs gain leverage as partners in dealmaking</title>
      <description>
        <![CDATA[China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said during the Chinabio Partnering Forum in Shanghai April 28.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730670</guid>
      <pubDate>Tue, 28 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730670-chinese-biotechs-gain-leverage-as-partners-in-dealmaking</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2026/Chinabio-2026-partnering-4-28.webp?t=1777394174" type="image/jpeg" medium="image" fileSize="198615">
        <media:title type="plain">Chinabio 2026 partnering </media:title>
        <media:description type="plain">China’s evolution in the dealmaking arena was the hot topic of discussion on the first day of the Chinabio Partnering Forum.</media:description>
      </media:content>
    </item>
    <item>
      <title>Ribo, Diagens tally 2 Hong Kong biotech, medtech IPOs in Q1 2026 </title>
      <description>
        <![CDATA[Ribo Life Science Co. Ltd.’s HK$1.8 billion (US$230 million) raise on Jan. 9 was the sole Chinese biotech IPO on the Hong Kong Stock Exchange in the first quarter (Q1) of 2026, despite a growing backlog of more than 70 filings from China life science firms in 2025. Among med-tech companies, Hangzhou Diagens Biotechnology Co. Ltd. debuted with a $101 million Hong Kong IPO March 30, 2026.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730619</guid>
      <pubDate>Fri, 24 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730619-ribo-diagens-tally-2-hong-kong-biotech-medtech-ipos-in-q1-2026</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Hong-Kong-HKEX.webp?t=1588782956" type="image/png" medium="image" fileSize="582891">
        <media:title type="plain">Hong Kong stock market illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Akeso sets durability bar as immuno-oncology 2.0 race heats up </title>
      <description>
        <![CDATA[Akeso Pharmaceuticals Inc. has raised the bar for next-generation immuno-oncology, reporting more than 23 months median overall survival in pancreatic cancer with its PD-1/CTLA-4 bispecific antibody cadonilimab, as emerging competitors begin to post earlier signals across solid tumors at the American Association for Cancer Research annual meeting in San Diego April 17 to 22.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730500</guid>
      <pubDate>Wed, 22 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730500-akeso-sets-durability-bar-as-immuno-oncology-20-race-heats-up</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Endocrine-metabolic-pancreas-anatomy-illustration.webp?t=1774020868" type="image/jpeg" medium="image" fileSize="655771">
        <media:title type="plain">Pancreas anatomy illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Xuanzhu shares dip despite phase III ALK inhibitor data</title>
      <description>
        <![CDATA[Xuanzhu Biopharmaceutical Co. Ltd. reported positive data from a local phase III study of dirozalkib (Xuan Fei Ning), an ALK inhibitor approved in China to treat patients with advanced non-small-cell lung cancer.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730579</guid>
      <pubDate>Tue, 21 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730579-xuanzhu-shares-dip-despite-phase-iii-alk-inhibitor-data</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/Lung-cancer-illustration.webp?t=1621625770" type="image/png" medium="image" fileSize="543175">
        <media:title type="plain">Lung cancer illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Mabwell turns to Hong Kong to fund ADC ambitions</title>
      <description>
        <![CDATA[Following its 2022 debut on Shanghai’s STAR Market, Mabwell (Shanghai) Bioscience Co. Ltd. is aiming to raise up to HK$1.44 billion (US$184.78 million) in an IPO on the Hong Kong Stock Exchange to advance its Nectin4-targeting antibody-drug conjugate (ADC) 9MW-2821 (bulumtatug fuvedotin).]]>
      </description>
      <guid>http://www.bioworld.com/articles/730578</guid>
      <pubDate>Tue, 21 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730578-mabwell-turns-to-hong-kong-to-fund-adc-ambitions</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/HKEX-exterior.webp?t=1632868875" type="image/png" medium="image" fileSize="621948">
        <media:title type="plain">HKEX exterior</media:title>
        <media:description type="plain">Credit: Lewis Tse Pui Lung - stock.adobe.com</media:description>
      </media:content>
    </item>
    <item>
      <title>Early data position Junshi in next-gen immuno-oncology race </title>
      <description>
        <![CDATA[Shanghai Junshi Biosciences Co. Ltd reported early clinical signals across its next-generation immuno-oncology pipeline, including response rates of up to 71% in metastatic colorectal cancer and 45.5% in hepatocellular carcinoma, at the American Association for Cancer Research meeting in San Diego.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730486</guid>
      <pubDate>Tue, 21 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730486-early-data-position-junshi-in-next-gen-immuno-oncology-race</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/Cancer-cells-and-immunotherapy.webp?t=1623784162" type="image/png" medium="image" fileSize="495987">
        <media:title type="plain">Illustration of cancer cells and immunotherapy treatment</media:title>
      </media:content>
    </item>
    <item>
      <title>Biogen amasses full felzartamab rights with $850M TJ deal </title>
      <description>
        <![CDATA[Biogen Inc. has consolidated full global rights to felzartamab through an $850 million deal with TJ Biopharma Co. Ltd. April 20, closing the chapter on a complex 10-year license saga. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/730485</guid>
      <pubDate>Tue, 21 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730485-biogen-amasses-full-felzartamab-rights-with-850m-tj-deal</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Global-handshake-silhouette.webp?t=1670353285" type="image/png" medium="image" fileSize="178881">
        <media:title type="plain">Global handshake silhouette</media:title>
      </media:content>
    </item>
    <item>
      <title>Medtronic leads $100M financing round for Pulnovo</title>
      <description>
        <![CDATA[Pulnovo Medical Ltd. secured $100 million in a financing round led by Medtronic plc for its pulmonary artery denervation system to treat pulmonary hypertension. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/730471</guid>
      <pubDate>Mon, 20 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730471-medtronic-leads-100m-financing-round-for-pulnovo</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Money-financing.webp?t=1588371985" type="image/png" medium="image" fileSize="253228">
        <media:title type="plain">Hand holding gear, dollar sign</media:title>
      </media:content>
    </item>
    <item>
      <title>Xuanzhu shares dip despite phase III ALK inhibitor data</title>
      <description>
        <![CDATA[Xuanzhu Biopharmaceutical Co. Ltd. reported positive data from a local phase III study of dirozalkib (Xuan Fei Ning), an ALK inhibitor approved in China to treat patients with advanced non-small-cell lung cancer.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730470</guid>
      <pubDate>Mon, 20 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730470-xuanzhu-shares-dip-despite-phase-iii-alk-inhibitor-data</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/Lung-cancer-illustration.webp?t=1621625770" type="image/png" medium="image" fileSize="543175">
        <media:title type="plain">Lung cancer illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Mabwell turns to Hong Kong to fund ADC ambitions</title>
      <description>
        <![CDATA[Following its 2022 debut on Shanghai’s STAR Market, Mabwell (Shanghai) Bioscience Co. Ltd. is aiming to raise up to HK$1.44 billion (US$184.78 million) in an IPO on the Hong Kong Stock Exchange to advance its Nectin4-targeting antibody-drug conjugate (ADC) 9MW-2821 (bulumtatug fuvedotin).]]>
      </description>
      <guid>http://www.bioworld.com/articles/730409</guid>
      <pubDate>Mon, 20 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730409-mabwell-turns-to-hong-kong-to-fund-adc-ambitions</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/HKEX-exterior.webp?t=1632868875" type="image/png" medium="image" fileSize="621948">
        <media:title type="plain">HKEX exterior</media:title>
        <media:description type="plain">Credit: Lewis Tse Pui Lung - stock.adobe.com</media:description>
      </media:content>
    </item>
    <item>
      <title>CSPC’s SYS-6051 cleared for clinic in China for solid tumors</title>
      <description>
        <![CDATA[CSPC Pharmaceutical Group Ltd.’s SYS-6051 has gained clinical trial clearance from China’s National Medical Products Administration (NMPA) for advanced solid tumors. SYS-6051 is a human tissue factor-targeted antibody-drug conjugate that binds to tissue factor expressed on the surface of tumor cells.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730429</guid>
      <pubDate>Thu, 16 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730429-cspcs-sys-6051-cleared-for-clinic-in-china-for-solid-tumors</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Drugs/Antibody-drug-conjugates-ADCs-3D.webp?t=1751620465" type="image/jpeg" medium="image" fileSize="160333">
        <media:title type="plain">3D rendering of an antibody-drug conjugate</media:title>
      </media:content>
    </item>
    <item>
      <title>China’s NMPA accepts Mabwell’s IND application for 6MW5311</title>
      <description>
        <![CDATA[Mabwell (Shanghai) Bioscience Co. Ltd.’s has announced IND acceptance by China’s National Medical Products Administration (NMPA) for the company’s LILRB4/CD3 T-cell engager bispecific antibody 6MW5311. The drug candidate is being developed for hematologic malignancies, specifically acute myeloid leukemia (AML), chronic myelomonocytic leukemia and multiple myeloma.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730428</guid>
      <pubDate>Thu, 16 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730428-chinas-nmpa-accepts-mabwells-ind-application-for-6mw5311</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/AML-cells-acute-myeloid-leukemia.webp?t=1663340307" type="image/png" medium="image" fileSize="1258935">
        <media:title type="plain">Microscopic image of acute myeloid leukemia (AML) cells.</media:title>
        <media:description type="plain">Acute myeloid leukemia cells. Credit: Cincinnati Children's
</media:description>
      </media:content>
    </item>
    <item>
      <title>Mabwell announces Chinese clinical trial clearance for SST-001</title>
      <description>
        <![CDATA[Mabwell (Shanghai) Bioscience Co. Ltd. has announced that SST-001 (18F-FD4), an α-synuclein-targeted PET tracer developed by Mabwell’s incubated company Synusight Biotech, has received clinical trial clearance from China’s National Medical Products Administration (NMPA). The planned phase I trial will enroll healthy volunteers, patients with multiple system atrophy (MSA), and patients with Parkinson’s disease.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730374</guid>
      <pubDate>Wed, 15 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730374-mabwell-announces-chinese-clinical-trial-clearance-for-sst-001</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Drugs/Radiopharmaceutical-illustration.webp?t=1680558525" type="image/png" medium="image" fileSize="129994">
        <media:title type="plain">Radiopharmaceutical illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>New China biotech Syneron chases macrocycle frontier</title>
      <description>
        <![CDATA[Syneron Bio is emerging as one of the most heavily backed new entrants in the macrocyclic peptide space, raising more than $250 million in venture funding and securing a multibillion-dollar deal with Astrazeneca plc as it builds a platform spanning several of the most competitive frontiers in drug development.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730420</guid>
      <pubDate>Tue, 14 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730420-new-china-biotech-syneron-chases-macrocycle-frontier</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Research-and-science/Multicolor-peptide-illustration.webp?t=1775668991" type="image/jpeg" medium="image" fileSize="534333">
        <media:title type="plain">Multicolor peptide illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>New China biotech Syneron chases macrocycle frontier</title>
      <description>
        <![CDATA[Syneron Bio is emerging as one of the most heavily backed new entrants in the macrocyclic peptide space, raising more than $250 million in venture funding and securing a multibillion-dollar deal with Astrazeneca plc as it builds a platform spanning several of the most competitive frontiers in drug development.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730152</guid>
      <pubDate>Wed, 08 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730152-new-china-biotech-syneron-chases-macrocycle-frontier</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Research-and-science/Multicolor-peptide-illustration.webp?t=1775668991" type="image/jpeg" medium="image" fileSize="534333">
        <media:title type="plain">Multicolor peptide illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Fosun gains clinical trial approval in China for FXB-0871</title>
      <description>
        <![CDATA[Fosun Pharmaceutical (Group) Co. Ltd. has received the approval from China’s National Medical Products Administration (NMPA) to initiate a clinical trial of FXB-0871 (TEV-56278) for the treatment of locally advanced or metastatic solid tumors.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730093</guid>
      <pubDate>Thu, 02 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730093-fosun-gains-clinical-trial-approval-in-china-for-fxb-0871</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/Cancer-tumor-blood-vessels.webp?t=1691420296" type="image/jpeg" medium="image" fileSize="242637">
        <media:title type="plain">3D illustration of tumor</media:title>
      </media:content>
    </item>
  </channel>
</rss>
